Mary Kay Awards Doctoral Dissertation Awards at 2019 Academy of Marketing Science Annual Conference

The AMS Mary Kay Doctoral Dissertation Awards provide doctoral students with funding needed to complete their educational journeys

DALLAS-Tuesday 4 June 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Mary Kay, an international leader in corporate and social responsibility, today announced winners of the Mary Kay Doctoral Dissertation and Doctoral Dissertation Proposal Awards at the 2019 Academy of Marketing Science Annual Conference in Toronto. The awards, which have been provided annually by the iconic beauty company for more than 25 years, celebrate doctoral candidates in marketing based on the quality of their dissertation research and their final presentations at the AMS Annual Conference.

Doctoral students from programs at any recognized university, college of higher learning, business school or management school worldwide were eligible for the AMS Mary Kay Doctoral Dissertation Awards. This year’s winners were:

2019 Mary Kay Doctoral Dissertation Proposal Award
1. Shaobo Li, Nanyang Technological University, Singapore

2. Junzhou Zhang, Old Dominion University

2019 Mary Kay Doctoral Dissertation Award

1. Kiran Pedada, Texas Tech University

2. Anh Dang, Old Dominion University

3. Martin Hirche, Ehrenberg-Bass Institute for Marketing Science, University of South Australia

“Mary Kay fosters a culture of innovation, empowerment and continuous education with our independent sales force and employees around the world,” said Beth Lopez, Vice President of Global Sales Education for Mary Kay. “We were so impressed by the dissertation presentations at this year’s AMS Annual Conference. We look forward to providing mentorship and networking opportunities to our winners as they pursue their noble goal of continuous education.”

Michelle Haurilak, Director of PR, Digital & Product Marketing of Mary Kay Canada, announced the winners of the Mary Kay Dissertation Award and the Mary Kay Dissertation Proposal Award during the awards banquet lunch on Thursday, May 30.

“The Mary Kay Dissertation Competition is an important part of the Academy of Marketing Science Annual Conference,” said O.C. Ferrell, President of The Academy of Marketing Science. “Mary Kay’s involvement provides an opportunity for finalists to network with Mary Kay executives. Improving industry connections for doctoral students is a major objective of the competition. We sincerely appreciate Mary Kay’s commitment to this event.”

For more information about the Academy of Marketing Science, click here.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay FoundationSM, the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

About The Academy of Marketing Science

The Academy of Marketing Science is a non-profit, international, scholarly, professional organization. It is dedicated to promoting high standards and excellence in the creation and dissemination of marketing knowledge and the furtherance of marketing practice through a role of leadership within the discipline of marketing around the world. The Academy is committed to the highest ethical standards and collegiality in the pursuit of this mission.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005474/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com


Permalink : https://www.aetoswire.com/news/mary-kay-awardsnbspdoctoral-dissertation-awards-at-2019-academy-of-marketing-science-annual-conference/en

Takeda Makes First Private Sector Pledge for Global Fund Replenishment

GENEVA & OSAKA, Japan-Tuesday 4 June 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion over five years, builds on Takeda's previous contribution to the Global Fund.

Takeda, a leading global pharmaceutical company headquartered in Japan, intends to support the improvement of maternal and child health by integrating quality HIV, tuberculosis and malaria services in antenatal and postnatal care in several countries in Africa.

“We are very pleased to renew our partnership with Takeda and strengthen our collaboration in fighting HIV, TB and malaria,” said Peter Sands, Executive Director of the Global Fund. “I hope Takeda’s vote of confidence in the work we do will encourage other corporations in Asia and beyond to step up the fight to end the epidemics.”

Takeda’s first pledge of JP ¥ 1 billion over ten years was invested in strengthening the capacity of health care workers in Africa. It helped boost malaria prevention efforts in Tanzania with the distribution of mosquito nets; accelerated access to TB treatment in Kenya; and expanded HIV services and increased awareness of the virus in Nigeria.

“We are deeply inspired by the Takeda Initiative’s impact on strengthening healthcare workforce capacity in Kenya, Nigeria, and Tanzania to prevent and address the world’s three biggest infectious disease killers,” said Christophe Weber, President & CEO, Takeda Pharmaceutical Company. “Our commitment to Better Health and a Brighter Future extends beyond our work at the cutting edge of innovation to bold, long-term investments in disease prevention, capacity building, and access to healthcare in partnership with the global community. Supporting the Global Fund over the past 10 years has yielded results that are very important to us, and that is why we are proud to continue to partner with the Global Fund on the Takeda Initiative 2.”

The Global Fund has demonstrated extraordinary impact as a public-private partnership, saving 27 million lives since 2002. The number of people dying from AIDS, TB and malaria in countries where the Global Fund invests has been reduced by one-third.

France will convene the Global Fund’s Sixth Replenishment pledging conference on October 10, 2019 in Lyon, France. The Global Fund seeks to raise at least US$14 billion – US$1 billion from the private sector – for the next three years. The funds will help save 16 million lives, cut the mortality rate from HIV, TB and malaria in half, and build stronger health systems by 2023.

The renewal of the partnership was facilitated by the Friends of the Global Fund, Japan, operated by the Japan Center for International Exchange. Akio Okawara, President & CEO of JCIE, added: “Takeda’s continued commitment to support the global fight against the three diseases provides an exemplary model of private sector engagement and adds momentum to Japan’s public-private partnership efforts in promoting universal health coverage and achieving the Sustainable Development Goals.”

About the Global Fund
The Global Fund is a 21st-century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As a partnership between governments, civil society, the private sector and people affected by the diseases, the Global Fund mobilizes and invests nearly US$4 billion a year to support programs run by local experts in more than 100 countries. By challenging barriers and embracing innovative approaches, we are working together to better serve people affected by the diseases.
For more information, visit www.theglobalfund.org

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190602005021/en/

Contacts

Media Contacts
The Global Fund
Dominique De Santis
Email: dominique.desantis@theglobalfund.org
Tel: +41 78 911 5327

Takeda Pharmaceutical Company
Kazumi Kobayashi
Email: Kazumi.kobayashi@takeda.com
Tel : +81-3-3278-2095


Permalink : https://www.aetoswire.com/news/takeda-makes-first-private-sector-pledge-for-global-fund-replenishment/en

G+D Mobile Security and IDEMIA Intend to Create the White Label Alliance (WLA) to Define an Open Standard for Payment

COURBEVOIE, France-Tuesday 4 June 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Considering global market demand for independent and standardized payment solutions, G+D Mobile Security and IDEMIA announce their intention to create the White Label Alliance (WLA) to provide a new security solution for next generation payment applications. The solution will be based on White Label EMV specifications and will enable ready-to-deploy solutions for domestic payment schemes and closed-loop worldwide.

The new alliance is a response to the growing global demand for new, next-generation independent payment solutions. By providing global open standards that are governed by an independent body, the White Label Alliance (WLA) ensures that commercial solutions can be built on these specifications enabling innovative and competitive offerings. The White Label Alliance (WLA) aims to enable ready-to-deploy solutions for domestic payment schemes and closed-loop worldwide

The aim of the White Label Alliance (WLA) cooperation is to design and maintain an open, comprehensive and standardized framework to meet the requirements of open and closed payment systems. Based on the EMV standard, the White Label Alliance (WLA) solution ensures scalability for all technologies: for cards, terminals and mobile devices. Therefore the White Label Alliance is strongly committed to open standards to ensure additional value for the payment ecosystem.

For these reasons, the White Label Alliance (WLA) initiative encourages an ecosystem that enables innovations and competitive offerings based on a worldwide standard.

As the owner of the specifications, the White Label Alliance (WLA) will work on future-proof evolution of the solution being in line with demands of the members. In order to expand the network and to grow accessible payment schemes, the White Label Alliance (WLA) invites all interested payment stakeholders to join.

“The close cooperation of companies such as G+D Mobile Security and IDEMIA within the framework of the new alliance demonstrates the effort to define new open payment specifications that ultimately benefit all end users." explains Gabriele Bugat, Head of Financial Services Solutions at G+D Mobile Security. "We are also planning to gain more members for the new alliance later this year in order to put our plans on an even broader footing."

"Supporting open standards and delivering interoperable solutions has always been a key concern for our company. That is why we are very pleased to be part of this initiative," says Amanda Gourbault Executive Vice President for Financial Institutions activities at IDEMIA. "Based on our extensive experience in the development of EMV technology, we want to play a key role in creating an open alliance which will allow domestic payment networks, transport operators and closed loop retailers to deploy a truly independent solution based on proven technology, with a fast time to market.”

About G+D Mobile Security

G+D Mobile Security is a global mobile security technology group headquartered in Munich, Germany. The company is part of the Giesecke+Devrient Group. G+D Mobile Security has around 5,300 employees worldwide and generated sales of around 868 million euros in the 2018 financial year. More than 40 sales offices and more than 20 certified production and personalization locations worldwide ensure international customer proximity.

G+D Mobile Security manages and secures billions of digital identities over their entire lifecycle. Our products and solutions are used daily by banks, network operators, manufacturers of mobile devices and automobiles, health insurance companies, private and public transport companies and their customers to secure mobile payment, communication and interaction between devices. G+D Mobile Security holds a leading competitive and technological position in these markets. Further information can be found at https://www.gi-de.com/de/de/mobile-security

About Idemia

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005349/en/

Contacts
Christoph Lang
Giesecke+Devrient
press spokesman
corporate communications
Phone: +49 89 4119-2164
E-mail: christoph.lang@gi-de.com

IDEMIA / Havas PR agency
Email: idemia@havas.com


Permalink : https://www.aetoswire.com/news/g-d-mobile-security-and-idemia-intend-to-create-the-white-label-alliance-wla-to-define-an-open-standard-for-payment/en

COMPUTEX 2019 Ended Successfully

The Heat of Gaming Is Extended to the Battle of High-Performance Computing

TAIPEI-Monday 3 June 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- COMPUTEX 2019 closed today (June 1) with a huge success. In the last five days, 42,495 international buyers from 171 countries flooded into the show, a 0.5% growth from the previous year. The top 10 buyer countries are, namely, China, the US, Japan, South Korea, Hong Kong, Thailand, Singapore, Germany, Malaysia, and India. Once again, COMPUTEX established the role of a leading ICT tradeshow that connects businesses along industry supply chains and opens up infinite possibilities in the tech ecosystem. In addition, InnoVEX 2019 attracted 18,251 visitors in 3 days, a 3% from the previous year, showing significant startup dynamics. During the show, 76 heavyweight buyers from around the world participated in 470 sessions of one-on-one procurement meetings. Furthermore, InnoVEX invited 45 international venture capital firms, including Samsung NEXT, LINE, Delta, China Trust, and Israel's largest fundraising platform, OurCrowd, to match with 69 startups.

Myriads of Gaming Devices Launched; New-Generation High-Performance Products Glowed

With the advancements and introduction of new AAA games based on generous production budgets and marketing cost, PC manufacturers are taking up challenges to break technological boundaries. The development of high-performance multitasking processors, graphics cards, memory, and high-end peripherals is indicating that these brands are catering to professional eSports players and enthusiastic gamers, meeting their demands and expectations for immersive gaming experiences.

MSI’s flagship GT76 Titan gaming laptop showcased at COMPUTEX was armed with an Intel® Core™ i9 processor that can be overclocked to 5.0GHz across all 8 cores, while its extreme cooling capability handles the most extreme heat, granting the new GT Titan its overclocked desktop performance. ADATA showcased its XPG ORB that presents all XPG products and offers immersive experiences. ASRock introduced its Phantom Gaming motherboards while its premium Z390 Phantom Gaming X received the most attention at COMPUTEX for being the first motherboard in the world to support Wi-Fi 6 (802.11ax), providing improved thermal result and superior performance.

Inspiring eSports Games Held for Charity on the International Stage

As the first charity eSports event held at COMPUTEX, ZOTAC CUP Fight for Charity LOL Tournament ended today. A total Grand Finals prize pool of US$100,000 will go towards charities including Esports Foundation in the US, Gaming Aid in Germany and Make-A-Wish Foundation. ZOTAC successfully made positive impacts and give back for a good cause.

G.Skill OC World Record Stage 2019 and OC World Cup 2019—organized by G.Skill and sponsored by Samsung and Intel—ended with championship taken by Alex@ro from Romania. The 8th G.Skill OC World Record Overclocking Competition invited 15 overclockers to represent the major e-sports vendors to demonstrate the powerful hardware performance on the spot. And in addition to the overclocking contest, G.Skill Extreme Mod Stage 2019, on the other hand, invited 10 teams of talented system mod builders to bring their creativity into full play at COMPUTEX and presented 11 of the world’s most creative and special system mods.

Promising Startups From Around the World Gathered at InnoVEX, Pitch Competition Awards Delivered

As a global indicator, InnoVEX is a platform that encourages startups to show their unlimited creativity and offers publicity opportunities. Every year at InnoVEX, a pitch competition is held. This year, the total award reached US$420,000. The grand prize worthy of US$30,000 was taken by MedFluid. Omni Eyes, Mind & Idea Fly, Onesoftdigm, MedFluid, and PurCity left with Startup Terrace Awards and US$ 60,000. MTAMTech was awarded US$10,000 by Taiwania Capital and Ganzin technology received US$10,000 award by Qualcomm.

For the first time, a CEO Keynote was held with COMPUTEX pre-show International Press Conference with AMD President & CEO Dr. Lisa Su as the keynote speaker. Dr. Lisa Su addressed how the next-generation of computing will drive innovation. She also invited Microsoft, ASUS, Acer and close to 20 industry partners to present the computing industry ecosystem. Leonor Lin, TAITRA Executive Vice President said, “This year, we have seen various innovative applications driven by the advancements of AI, IoT, and 5G. The technologies to process a massive amount of data and high-performance computing will be one of the most important driving forces to sustain the growth of the tech industry in the future. COMPUTEX 2019 has fulfilled its promise to build global tech ecosystems. As the scope of exhibitions and the number of participants set new records, we expect COMPUTEX to keep leading technology businesses forward to build global technology ecosystems that bring prosperity to all.”

For more updated show info：

COMPUTEX Website：http://www.computextaipei.com.tw/zh_TW/
COMPUTEX Facebook：https://www.facebook.com/COMPUTEX.TAITRA/

About COMPUTEX TAIPEI (also called COMPUTEX):

Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.

About TAITRA:

Founded in 1970 to help promote foreign trade, the Taiwan External Trade Development Council (TAITRA) is the foremost non-profit trade promotion organization in Taiwan. Jointly sponsored by the government, industry associations, and several commercial organizations, TAITRA assists Taiwan businesses and manufacturers with reinforcing their international competitiveness and in coping with the challenges they face in foreign markets.

TAITRA boasts a well-coordinated trade promotion and information network of over 1,200 trained specialists stationed throughout its Taipei headquarters, five local branch offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, and 60 overseas branch offices worldwide. Together with its sister organizations, Taiwan Trade Center (TTC) and Taipei World Trade Center (TWTC), TAITRA has created a wealth of trade opportunities through effective promotion strategies.

In addition to organizing trade delegations & providing customized procurement services, TAITRA also hosts more than 35 international trade shows annually in Taipei and Kaohsiung.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190601005035/en/

Contacts

Press Contact:
Belinda Chen (TAITRA)
cpx-press1@taitra.org.tw

Permalink : https://www.aetoswire.com/news/computex-2019-ended-successfully/en

Moody’s Analytics Named Category Leader in Chartis IFRS 17 Report

LONDON-Monday 3 June 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Moody’s Analytics, a global provider of financial intelligence, has been named a Category Leader in "IFRS 17 Technology Solutions: Market and Vendor Landscape 2019", a new Chartis Research report that assesses 10 leading vendors of IFRS 17 solutions.

The report evaluates the vendors on six core capabilities. Moody’s Analytics was recognized for offering “Best-in-class” capabilities in three categories (data management, reporting, and validation and model capabilities) and “Advanced” capabilities in the other three (data warehouse, insurance contract qualification, and accounting recognition).

The Moody’s Analytics RiskIntegrity™ IFRS 17 platform is a cloud-enabled, out-of-the-box solution that helps insurers meet the stringent new reporting requirements of the International Financial Reporting Standard (IFRS) 17 accounting standard.

Designed to support the demanding needs of actuaries, accountants, and IT professionals, the platform comes with all the capabilities required for an efficient implementation of IFRS 17. It is available as a software-as-a-service solution.

“We’re thrilled that Chartis has recognized our IFRS 17 offering with the Category Leader distinction,” said Christophe Burckbuchler, Head of Insurance Strategy and IFRS 17 Solutions at Moody’s Analytics. “IFRS 17 presents insurers with many operational challenges, such as data preparation, modeling, and governance, that span actuarial and accounting functions. Our RiskIntegrity IFRS 17 solution works with our clients’ existing infrastructure and creates efficient processes that make it easy for these professionals to work together.”

Insurers interested in learning more about the RiskIntegrity IFRS 17 solution are encouraged to attend a complimentary IFRS 17 roadshow event. This series of events features Moody’s Analytics and insurance industry experts, who together examine the challenges—and opportunities—of IFRS 17 implementation. Events are currently taking place across Europe and in South Africa.

For the latest Moody’s Analytics IFRS 17 insight, visit our IFRS 17 Thought Leadership Center.

In the last year, Chartis Research has also recognized Moody’s Analytics Model Validation, CECL, Credit Risk (banking book), and Balance Sheet Management solutions with the Category Leader distinction.

Click here to learn more about the RiskIntegrity™ IFRS 17 solution.

About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE:MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.

About Chartis Research
Chartis Research is the leading provider of research and analysis on the global market for risk technology. It is part of Infopro Digital, which owns market-leading brands such as Risk and WatersTechnology. Chartis’ goal is to support enterprises as they drive business performance through improved risk management, corporate governance and compliance, and to help clients make informed technology and business decisions by providing in-depth analysis and actionable advice on virtually all aspects of risk technology. Further information is available at chartis-research.com.

RiskTech Quadrant®, RiskTech100® and FinTech Quadrant™ are registered trademarks of Infopro Digital Services Limited.

Contacts

JUSTIN BURSZTEIN
Moody’s Analytics Communications
001.212.553.1163
justin.bursztein@moodys.com

TRACEY SCOTT
Moody’s Analytics Communications
+44.207.772.5207
tracey.scott@moodys.com

Moody’s Analytics Media Relations

moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/

Permalink : https://www.aetoswire.com/news/moodyrsquos-analytics-named-category-leader-in-chartis-ifrs-17-report/en

New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluates Prevention of HAE Attacks with TAKHZYRO® (lanadelumab) During Early Treatment Phase

 Data Presented at European Academy of Allergy and Clinical Immunology Congress

OSAKA, Japan-Monday 3 June 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from an ad-hoc analysis of the Phase 3 HELP Study™, designed to evaluate the onset of action for TAKHZYRO® (lanadelumab) during days 0-69 of treatment. The analysis suggests that TAKHZYRO starts to prevent hereditary angioedema (HAE) attacks during this early treatment phase, with patients experiencing an 80.1% decrease in mean monthly attack rate compared to placebo.1 The results were presented today (PD0369) during the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of oedema (swelling) in various parts of the body.2,3

“The unpredictable nature of HAE attacks makes living with the disease physically and emotionally challenging for patients,” said Professor Marcus Maurer, M.D., Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité–Universitätsmedizin Berlin, Germany. “HAE requires an individualised approach to treatment, and it is important that a patient’s treatment plan helps reduce the frequency of attacks. These results are exciting as they suggest that lanadelumab begins to prevent HAE attacks during the initial phase of treatment.”

The ad-hoc analysis evaluated the efficacy of TAKHZYRO compared with placebo during days 0-69 of treatment using the same approach that was used to evaluate the primary and secondary endpoints during the complete study period (days 0-182).1 Results from the analysis showed that in patients receiving the recommended starting dose of TAKHZYRO 300 mg every two weeks, there was a significant reduction in mean monthly attack rate (80.1% decrease) compared to placebo (Adjusted P<0.001).1 During this initial treatment phase, patients treated with TAKHZYRO 300 mg every two weeks also experienced fewer severe attacks compared to placebo (7.4% vs. 22%) and were more likely to be HAE attack-free compared to those on placebo (48.1% vs. 7.3%).1

“Original data from the HELP Study showed that TAKHZYRO was effective in preventing HAE attacks over the entire duration of the study and, according to an exploratory analysis, many patients remained attack-free during the 16-week steady state period,” said Donatello Crocetta, M.D., Franchise Global Medical Unit Head, Rare Immunology and HAE at Takeda. “This new analysis supports previous study findings and builds on our understanding of how quickly TAKHZYRO can begin to help prevent HAE attacks, further supporting its use for appropriate patients as a preventive therapy that can be administered subcutaneously and begins to work rapidly.”

Across all TAKHZYRO treatment arms, (300 mg every two weeks, 300 mg every four weeks, 150 mg every four weeks), there was an improvement in mean monthly attack rate, monthly rate of moderate to severe attacks, monthly rate of attacks requiring acute treatment and the number of attack-free days, versus placebo, during the entire study period.1

The most commonly observed adverse reactions (52.4%) associated with TAKHZYRO were injection site reactions. Of these, 97% were of mild intensity. Hypersensitivity reaction (mild and moderate pruritus, discomfort and tingling of tongue) was observed (1.2%).4

TAKHZYRO 300 mg is approved in the European Union and Australia for the routine prevention of recurrent attacks of HAE in patients aged 12 years and older. TAKHZYRO 300 mg is approved as prophylaxis to prevent attacks of HAE in patients aged 12 years and older in the United States and for the routine prevention of attacks in patients aged 12 years and older in Canada.

The HELP Study™
The HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ was a multicentre, randomised, double-blind, placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered TAKHZYRO vs. placebo over 26 weeks in 125 patients 12 years of age or older with HAE.4

The primary endpoint of the HELP Study™ was the number of investigator-confirmed HAE attacks over the entire 26-week study duration. TAKHZYRO demonstrated that subcutaneous injections every two or four weeks reduced the mean monthly number of attacks across all three TAKHZYRO treatment arms studies: 300 mg every two weeks, 300 mg every four weeks and 150 mg of TAKHZYRO every four weeks. At 300 mg every two weeks, TAKHZYRO reduced the number of mean monthly HAE attacks by 87% vs. placebo (Adjusted P<0.001).4

Secondary endpoints included: 1) number of attacks requiring acute treatment and 2) number of attacks assessed as moderate or severe. Overall, each TAKHZYRO treatment arm demonstrated statistically significant attack rate reductions compared with placebo for all secondary efficacy endpoints (Adjusted P<0.001 for all comparisons), including: attacks requiring acute treatment (74% to 87%) and moderate or severe attacks (70% to 83%).4

Complete results from the Phase 3 HELP Study™ were published in the Journal of the American Medical Association (JAMA) on 27 November 2018.5

About Hereditary Angioedema
HAE is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The swelling can be debilitating and painful.2,3,6 Attacks that obstruct the airways can cause asphyxiation and are potentially life-threatening.3,6HAE affects an estimated 1 in 10,000 to 1 in 50,000 people worldwide. It is often under-recognised, under-diagnosed and under-treated.2,7

About TAKHZYRO® (lanadelumab)
TAKHZYRO (lanadelumab) is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.4

TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks in patients with HAE. TAKHZYRO is intended for the self-administration or administration by a caregiver, only after training by a healthcare professional.4

TAKHZYRO Safety Information for Europe
Please consult the TAKHZYRO Summary Product Characteristics (SmPC) before prescribing.

TAKHZYRO treatment should be initiated under the supervision of a physician experienced in the management of patients with hereditary angioedema (HAE). TAKHZYRO may be self-administered or administered by a caregiver only after training on SC injection technique by a healthcare professional.

Contraindication
Hypersensitivity to the active substance or to any of the excipients.

Warnings and Precautions
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, administration of TAKHZYRO must be stopped immediately and appropriate treatment must be initiated.

General: TAKHZYRO is not intended for treatment of acute HAE attacks. In case of a breakthrough HAE attack, individualized treatment should be initiated with an approved rescue medication. There are no available clinical data on the use of lanadelumab in HAE patients with normal C1-INH activity.

Interference with coagulation test: Lanadelumab can increase activated partial thromboplastin time (aPTT) due to an interaction of lanadelumab with the aPTT assay. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay. None of the increases in aPTT in patients treated with TAKHZYRO were associated with abnormal bleeding adverse events. There were no differences in international normalised ratio (INR) between treatment groups.

Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 'sodium-free'.

Interactions
No dedicated drug-drug interaction studies have been conducted. Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected.

As expected, concomitant use of the rescue medication C1 esterase inhibitor results in an additive effect on lanadelumab-cHMWK response based on the mechanism of action (MOA) of lanadelumab and C1 esterase inhibitor.

Immunogenicity
Treatment with lanadelumab has been associated with development of treatment emergent anti-drug antibodies (ADA) in 11.9% (10/84) of subjects. All antibody titres were low. The ADA response was transient in 20% (2/10) of ADA positive subjects. 2.4% (2/84) of lanadelumab-treated subjects tested positive for neutralizing antibodies.

The development of ADA including neutralising antibodies against TAKHZYRO did not appear to adversely affect the pharmacokinetic (PK) and pharmacodynamics (PD) profiles or clinical response.

Adverse Reactions
The most commonly observed adverse reaction (52.4%) associated with TAKHZYRO was injection site reactions (ISR) including injection site pain, injection site erythema and injection site bruising. Of these ISRs, 97% were of mild intensity, 90% resolved within 1 day after onset with a median duration of 6 minutes.

Hypersensitivity reaction (mild and moderate pruritus, discomfort and tingling of tongue) was observed (1.2%)


   


   


   



Very common (frequency ≥1/10):
   


   


   

Injection site reactions*

Common (≥1/100 to <1/10):
   


   


   

Hypersensitivity**, dizziness, rash maclo-papular, myalgia, alanine
aminotransferase increased, aspartate aminotransferase increased.

*Injection site reactions include: pain, erythema, bruising, discomfort, haematoma, haemorrhage, pruritus, swelling, induration, paraesthesia, reaction, warmth, oedema and rash.
** Hypersensitivity includes: pruritus, discomfort and tingling of tongue.

For full U.S. Prescribing Information, including the approved indication and important safety information, please visit https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

1 Riedl, MA et al. Lanadeluman demonstrates rapid and sustained prevention of hereditary angioedema attacks: Findings from the HELP study. Poster Presentation. European Academy of Allergy and Clinical Immunology. Lisbon, Portugal. June 2019.
2 Cicardi M, Bork K, Caballero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67(2):147-157.
3 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
4 TAKHZYRO® (lanadelumab) Summary of Product Characteristics.
5 Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
6 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
7 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005077/en/

Contacts

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933

Permalink : https://www.aetoswire.com/news/new-ad-hoc-analysis-of-phase-3-help-studytrade-evaluates-prevention-of-hae-attacks-with-takhzyroregnbsplanadelumab-during-early-treatment-phase/en

UAE, Uzbekistan Identify Practical Steps to Implement Government Modernization Program

 Partnership expands to include 120 initiatives covering 19 areas



Dubai, United Arab Emirates, -Monday 3 June 2019 [ AETOS Wire ]

Intensive meetings of the joint task forces of the UAE and Uzbekistan governments held lately resulted in identifying a series of practical steps to transfer the UAE's pioneering experience in government work to Uzbekistan within three years in line with implementing the partnership agreement in government modernization between the two countries.

The meetings took place during the visit of a high-level Uzbekistan government delegation to the UAE, led by His Excellency Aziz Abdukhakimov, Deputy Prime Minister of Uzbekistan, and included more than 60 ministers and senior government officials.

The two parties agreed to expand the scope of cooperation from 17 to 19 areas with the addition of taxation and human resources, as well as to implement 120 joint initiatives over the next three years, with 73 of these set for launch in 2019. Furthermore, they approved specific timeframes for activating the partnership agreement and finalizing the schedule of the joint initiatives with a focus on enhancing service efficiency and institutional performance, leadership qualification, and capacity building.

The strategic partnership leverages the UAE model of government work in modernization, performance measurement, best practice application, and service delivery to establish an innovation- and excellence-based system of government in Uzbekistan. Under the terms of the agreement, signed in April 2019, the two countries have formed expert task forces to support joint projects across 19 areas, including government strategy, government performance, government innovation, coding, future education, future economy, global competitiveness, and ease of doing business.

The collaboration is part of the UAE’s government knowledge exchange program. Within the framework of the initiative, the UAE has also signed partnership agreements in government modernization with Egypt, Jordan, Costa Rica and Portugal.

Contacts

APCO Worldwide

Tasnim Hijazi, Senior Account Manager, +971521607687

thijazi@apcoworldwide.com


Permalink : https://www.aetoswire.com/news/uae-uzbekistan-identify-practical-steps-to-implement-government-modernization-program/en